Contact

Aurelium Home About Services Treatment Comparison Safety & Considerations Research & Resources Contact Evidence, safety & regulatory context Ibogaine Ketamine Treatment A careful guide to an emerging, high-interest area where potential benefits, substantial uncertainty, and serious safety questions must be considered together. Aurelium is an independent resource on emerging psychedelic treatment questions. Complex interventions deserve clear evidence, rigorous screening, and unhurried questions. A measured starting point Two very different substances, one difficult question Ibogaine ketamine treatment is a phrase used for an emerging and unsettled space: people compare, sequence, or discuss ibogaine and ketamine around addiction, depression, PTSD, and other mental health conditions. It does not describe a single standardized or proven protocol. Ibogaine is a naturally occurring psychoactive alkaloid derived from the Tabernanthe iboga plant, primarily found in West Africa. Its basic pharmacological history includes traditional uses as well as modern interest in addiction treatment, but traditional uses do not establish safety or efficacy in contemporary clinical settings. Ketamine is a dissociative anesthetic. At sub-anesthetic doses, it acts as an N-methyl-D-aspartate NMDA receptor antagonist and is used in some clinical settings for depression and PTSD under medical supervision. The FDA explains that ketamine carries real risks outside appropriate oversight , including risks related to sedation, dissociation, and misuse. Because ibogaine has potential cardiac toxicity and ketamine has its own psychiatric and physiological considerations, a combined discussion should begin with caution rather than promises. People researching the topic can start with this independent overview of the treatment landscape while keeping the evidence for each substance distinct. 01 Evidence is uneven Research studies exist for each substance, but robust clinical trials on the

A place for careful feedback.